What question did this study set out to answer?

To explore the impact of Panton-Valentine leukocidin (PVL) producing Staphylococcus aureus on the severity of acute hematogenous osteomyelitis in pediatric patients.

April 15, 2026

Panton-Valentine Leukocidin Producing Staphylococcus aureus Causing Acute Hematogenous Osteomyelitis in the Pediatric Population: Implications on Clinical Course and Outcome

Key Points

To explore the impact of Panton-Valentine leukocidin (PVL) producing Staphylococcus aureus on the severity of acute hematogenous osteomyelitis in pediatric patients.
Analyzed clinical courses of pediatric patients with PVL-positive S. aureus infections.
Documented incidence of severe cases and associated complications like subperiosteal abscess.
Observed treatment outcomes and necessity for surgical interventions.
97.3% of patients tested positive for PVL-producing S. aureus.
A significant portion exhibited severe clinical courses requiring intervention.
Subperiosteal abscesses were common, necessitating surgical drainage in many cases.

Abstract

Despite almost a third of the study participants having a severe clinical course of disease, 97.3% of the patients tested positive for a PVL-producing S. aureus strain, suggesting that having a severe clinical course ismultifactorial. Given the high number of PVL-positive cases, we postulate that these bacteria cause AHOM with subperiosteal abscess formation requiring surgical drainage in our population.

Panton-Valentine Leukocidin Producing Staphylococcus aureus Causing Acute Hematogenous Osteomyelitis in the Pediatric Population: Implications on Clinical Course and Outcome

Key Points

Abstract

Cite This Study